Fibroblasts expressing the tumor suppressor p16INK4a (a marker of senescence) stimulated lung stem cells from young mice to repair damaged tissue, according to a study from the University of California, San Francisco (UCSF). The finding calls into question therapies that eliminate these senescent cells without considering their beneficial role in tissue homeostasis. Read More
Investigators from the University of Copenhagen, Denmark have developed a cell line engineered to express bone morphogenetic protein 2 (BMP-2) and key extracellular matrix genes and critical factors that regulate and support human hematopoiesis. The findings were reported in the Oct. 12, 2022, issue of Science Translational Medicine. One of the clinical applications that the research team is interested in involves exploiting the MSOD-B hOss as a tumor model for bone colonization in the context of various cancers. Read More
Glaucoma is an eye disease that damages the optic nerve, with the main cause being ocular hypertension due to high resistance to the outflow of aqueous humor. Read More
Loss of Paneth cells and their antimicrobial granules has been linked to a compromised intestinal epithelial barrier, which is a hallmark of Crohn’s disease. Read More
Lucy Therapeutics Inc. has announced promising preclinical data for multiple compounds in its lead program for Parkinson's disease, including two lead small-molecule agents, LucyTx-1209 and LucyTx-1212. Read More
Kriya Therapeutics Inc. has presented preclinical data on their novel candidate, KT-A261, an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab, administered as a single intravitreal injection to improve ocular concentrations of adalimumab, for the potential treatment of noninfectious uveitis (NIU). Read More
Hangzhou Apeloa Medicine Research Institute Co. Ltd. and Apeloa Pharmaceutical Co. Ltd. have disclosed fibroblast growth factor receptor 4 (FGFR-4) inhibitors reported to be useful for the treatment of cancer. Read More
Adlai Nortye Ltd. has described mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders. Read More
Patients with Alzheimer’s disease (AD) often show increased levels of circulating pro-inflammatory mediators and altered antibody levels in the blood. Read More
Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis. Read More
Researchers from the University of Texas Medical Branch at Galveston have published preclinical data from a study that aimed to assess the role of gut microbiota-reactive Th17 cells in intestinal fibrosis, which is a significant complication of Crohn’s disease (CD). Read More
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Read More
